🇺🇸

US SEC Filing Intelligence

· daily

US SEC Trading Suspension Halt Orders — July 16, 2026

The three filings in this trading suspensions stream present a mixed landscape for small-cap companies listed on US exchanges. Cycurion, Inc. faces imminent delisting from Nasdaq due to a prolonged bid price deficiency, with no compliance period available after a prior reverse split, creating a high-risk event for shareholders. TG-17, Inc. (Our Bond, Inc.) has received multiple non-compliance notifications for bid price and market value thresholds, but retains a 180-day cure period, offering a potential turnaround window. In contrast, SRx Health Solutions, Inc. (SRX Global Inc.) has resolved its NYSE American deficiency, marking a positive compliance event that removes delisting risk. Period-over-period comparisons are limited as filings are event-driven, but the divergence in outcomes—one delisting, one at risk, one compliant—highlights the binary nature of regulatory compliance for micro-cap equities. No insider trading, capital allocation, or forward-looking guidance data was provided in these filings, limiting trend analysis but emphasizing the criticality of exchange listing status as a catalyst.

3 high priority 3 total filings
· daily

US Executive Officer Management Changes SEC — July 16, 2026

This digest of 28 filings reveals a bifurcated market for executive and director changes, with most transitions being routine succession planning or governance adjustments, but a few high-conviction signals stand out. The most critical development is the leadership upheaval at BioRestorative Therapies, where the CEO and CFO resigned claiming a Change in Control, triggering a material uncertainty and potential $2.85M severance liability. Conversely, Snowflake’s board granted CEO Sridhar Ramaswamy a highly ambitious performance-based RSU award with escalating stock price targets up to $531, signaling strong alignment with long-term value creation. Harmony Biosciences delivered a standout operational performance with record Q2 revenue of $261M (up 30% YoY), but the simultaneous departure of its CFO creates a mixed signal. Sector themes include a notable cluster of biotech board appointments (Arcutis, enGene, Gyre Therapeutics) as companies prepare for key regulatory milestones, and a trend of founder/family-led CEO successions at John B. Sanfilippo & Son and Destiny Media Technologies. Overall, the data suggests a market where management teams are positioning for growth, but investors should scrutinize the few situations where insider departures coincide with governance disputes or financial uncertainty.

28 high priority 28 total filings
· daily

US Bankruptcy Chapter 11 Insolvency SEC Filings — July 16, 2026

Inotiv, Inc. has received court confirmation of its prepackaged Chapter 11 plan, marking a definitive end for common equity holders. The plan cancels all 35,172,908 existing shares with zero recovery, while issuing 5,100,000 new shares and warrants to prepetition lenders. The company's Nasdaq delisting was finalized in July 2026, and shares now trade OTC under NOTVQ. This is a total loss event for shareholders, with no forward-looking guidance or insider activity to suggest any recovery. The filing underscores the finality of the restructuring, with no operational or financial metrics to compare, as the company will emerge as a private entity.

1 high priority 1 total filings
· daily

US Corporate Board Director Changes SEC Filings — July 16, 2026

The 28 filings reveal a mix of strategic board strengthening and leadership turmoil. Key themes include governance improvements (ProCap achieving Nasdaq compliance, BioRestorative addressing board gaps), biotech board expansions with experienced leaders (Arcutis, Gyre, enGene), and planned succession (Sanfilippo, PJT Partners, Union Bankshares). However, notable risks emerge from BioRestorative's disputed change-in-control and potential $2.85M severance, Harmony's CFO departure despite strong revenue growth (30% YoY), and several unexplained departures (Unity, Arhaus). Positive signals come from enGene's regulatory catalysts (pre-BLA meeting in 2H 2026) and Harmony's record revenue. The data underscores the importance of monitoring these transitions for execution risk and strategic shifts.

28 high priority 28 total filings
· daily

USA Insider Trading Pulse — July 16, 2026

Today's insider trading pulse reveals a bifurcated market: significant insider selling at Sea Ltd and Essent Group, contrasted by notable insider buying at Ares Dynamic Credit Allocation Fund and Sterling Real Estate Trust. The period-over-period data highlights a pattern of executive stock option awards at Atour Lifestyle and New Oriental Education, suggesting long-term incentive alignment but also creating potential overhang. The most critical development is the $5.13M sale by Essent Group's CEO under a 10b5-1 plan, which, while pre-arranged, signals a potential top. Conversely, the $4M purchase of preferred shares by a 10% owner at Ares Dynamic Credit Allocation Fund is a strong vote of confidence. Overall, the data suggests a cautious stance in high-growth tech (Sea Ltd) and financial services (Essent), while value/income plays (Ares, Sterling) are attracting insider capital.

50 high priority 50 total filings
· daily

US Merger & Acquisition SEC Filings — July 16, 2026

Today's M&A digest reveals a bifurcated US deal landscape: large-cap strategic consolidation (Baker Hughes/Chart Industries) versus distressed restructurings and SPAC extensions. The $4.3B Baker Hughes-Chart merger closed, creating a new industrial gas/cryogenics segment with $325M in targeted cost synergies, signaling confidence in energy transition and data center demand. Conversely, SpringBig's distressed asset transfer to lenders and Mainz Biomed's mixed-progress facility acquisition highlight execution risks in smaller-cap deals. Plum Acquisition Corp. IV's extension to July 2027 underscores ongoing SPAC challenges in finding viable targets. Catalyst Pharmaceuticals' post-merger charter amendments suggest a completed but undisclosed transaction. Key period-over-period trends are limited as most filings lack historical financials, but the Baker Hughes deal's 1.0-1.5x net leverage target within 24 months indicates disciplined balance sheet management post-acquisition. The overarching theme is a 'haves vs. have-nots' M&A environment where well-capitalized acquirers pursue transformative deals while distressed entities seek lifelines.

6 high priority 6 total filings
· monthly

US Pre-Market SEC Filings Roundup — July 16, 2026

Overnight SEC filings from July 15-16, 2026, reveal a mixed landscape of strong earnings, insider profit-taking, and significant corporate restructurings. UnitedHealth Group reported Q2 adjusted EPS of $6.38 (up 23.4% YoY) and raised full-year guidance, but membership declined by 525,000 sequentially, signaling a structural headwind. Insider selling was notable, with Clear Secure's CEO and director entity selling ~$10M combined and Essent Group's Chairman selling $5.13M, suggesting management may see current valuations as attractive for exits. Inotiv's Chapter 11 confirmation wiped out equity holders entirely, while XOMA Royalty's Nasdaq delisting and Senti Biosciences' potential 77.5% dilution highlight severe risks in small-cap biotech. On the positive side, capital returns accelerated: KB Financial completed a KRW 600B buyback (1.01% of shares) and plans cancellation, and Dorian LPG declared a $1.00 special dividend. Awareness Group's revenue surged 1,045% YoY, though it remains in negative equity. The overnight filings also revealed governance issues at IRIDEX (stealth proxy campaign) and notable acquisition activity by NextPlat and Stereotaxis. Overall, investors should focus on the dichotomy between strong earnings at large caps and severe dilution/bankruptcy risks in smaller names.

30 high priority 20 medium 50 total filings
· daily

Biotech Small-Cap Approvals — July 15, 2026

During the period of July 15, 2026, the FDA approved 4 biosimilar/fallback products, with zero NMEs, zero label expansions, and zero biosimilars (as defined by the stream's mix). All approvals are classified as 'Other' fallback entries, generating 4 neutral signals with no bullish or bearish catalysts. The dominant theme is generic/biosimilar market entries by small-cap sponsors including LAURUS, BELOTECA, APOTEX, and SQUARE PHARMS PLC, targeting established molecules (RILPIVIRINE HYDROCHLORIDE, ILOPROST, MAGNESIUM SULFATE, and an undisclosed drug). The highest-conviction signal is the lack of novel drug approvals, indicating a quiet period for pipeline-driven catalysts. Key risks include limited commercial differentiation and pricing pressure in mature therapeutic categories, with no IRA exposure flags due to the absence of branded drugs.

4 total filings
· daily

Big Pharma Approvals — July 15, 2026

This period's FDA digest covers a single label expansion approval for Eli Lilly's abemaciclib (Verzenio), classified as a 'fallback' type with a modest bullish signal. The approval mix is zero NMEs, zero biosimilars, and zero standard label expansions, making this a low-velocity week for new drug catalysts. The dominant signal is Eli Lilly's continued lifecycle management of its CDK4/6 inhibitor franchise, though the lack of commercial details (peak sales, pricing, exclusivity) limits conviction. Key watch items include potential competitive dynamics from Novartis' Kisqali and Pfizer's Ibrance in the adjuvant breast cancer setting, as well as IRA exposure risk for this small molecule. Investors should view this as a maintenance event rather than a transformative catalyst.

1 total filings
· daily

New Drug Approvals (Original) — July 15, 2026

The July 15, 2026 approval stream delivered four biosimilar/fallback approvals with zero NMEs, zero label expansions, and zero biosimilar designations explicitly flagged, resulting in a neutral signal across all events. The period lacked therapeutic area clustering, as approvals spanned RILPIVIRINE HYDROCHLORIDE (Laurus), ILOPROST (Beloteca), an undisclosed agent from Apotex, and MAGNESIUM SULFATE (Square Pharms PLC) — none with disclosed peak sales, exclusivity, or pricing data. The highest-conviction signal is the absence of any NME or breakthrough therapy approval, indicating a low-catalyst week for innovative biotech investors. Key risk: the lack of commercial detail on all four approvals limits actionable investment conclusions, and the undisclosed Apotex approval introduces opacity risk for competitive dynamics in its target market.

4 total filings
· daily

New Federal Contractors — July 15, 2026

The single contract in this period, a $83.4 million delivery order from the USDA to EPSILON INC (a subsidiary of AMERICAN SYSTEMS CORPORATION), is entirely civilian and carries a neutral signal. The contract provides long-term revenue visibility through 2032 but is firm-fixed-price, transferring cost risk to the contractor. The award under full-and-open competition with a Service Disabled Veteran Owned Small Business preference suggests policy-driven access rather than a pure competitive moat. Key risks include federal budget uncertainty affecting option exercise and execution risk on a fixed-price IT support contract. The highest-conviction signal is the potential $346.5 million total value if all options are exercised, but this remains contingent on USDA budget cycles and performance satisfaction.

1 total filings
· daily

Significant Contract Modifications ($10M+) — July 15, 2026

This digest covers a single $83.4 million civilian contract modification awarded to EPSILON INC, a subsidiary of AMERICAN SYSTEMS CORPORATION, by the Department of Agriculture for DISC IT support services. The contract is entirely civilian, with no defense-related awards in the period. The highest-conviction signal is the long-term revenue visibility through 2032, though the firm-fixed-price structure and reliance on option exercise create execution and budget risk. Key watch items include USDA option announcements and parent company financial disclosures for revenue realization.

1 total filings
· daily

Contract Deobligations Alert — July 15, 2026

This single-record digest covers a $83.4 million civilian deobligation from the USDA to EPSILON INC, a subsidiary of AMERICAN SYSTEMS CORPORATION, for DISC IT support services. The award is entirely civilian, with zero defense exposure, and carries a neutral signal strength of 6/10. The highest-conviction signal is the long-term revenue visibility through 2032, but this is tempered by execution risk from the firm-fixed-price structure and the fact that this is a deobligation alert, not a new award. The key risk is federal budget uncertainty under a potential Continuing Resolution, which could delay option exercise on the $346.5 million ceiling.

1 total filings
· daily

Contract Option Exercises — July 15, 2026

This digest covers a single, large civilian contract option exercise totaling $83.4 million, with zero defense-related activity. The sole award is a 10-year, firm-fixed-price delivery order from the USDA to EPSILON INC, a subsidiary of AMERICAN SYSTEMS CORPORATION, for DISC IT support services. The contract's long duration through 2032 provides high revenue visibility, but the fixed-price structure places execution risk on the contractor. The highest-conviction signal is neutral, as the award is a stable, recurring civilian IT need, but the lack of defense exposure and medium pricing risk temper the bullish case. Key watch items include future option exercises and USDA budget stability under a potential Continuing Resolution.

1 total filings
· daily

Federal IT & Cybersecurity Contracts — July 15, 2026

This single-contract digest covers a $83.4 million civilian IT award from the Department of Agriculture to EPSILON INC, a subsidiary of AMERICAN SYSTEMS CORPORATION, with zero defense-related activity. The dominant theme is long-duration civilian IT support services, with the contract running through 2032 and a potential total value of $346.5 million if all options are exercised. The highest-conviction signal is neutral: the contract provides multi-year revenue visibility for AMERICAN SYSTEMS CORPORATION, but the firm-fixed-price structure places execution risk on the contractor. A key risk is that federal budget uncertainty under a potential Continuing Resolution could delay or cancel option exercises, particularly given the civilian agency context.

1 total filings
· daily

High-Value Federal Grants ($5M+) — July 15, 2026

This digest covers a single high-value civilian grant: an $83.4 million firm-fixed-price delivery order from the USDA to EPSILON INC (a subsidiary of AMERICAN SYSTEMS CORPORATION) for DISC IT support services, with a total potential value of $346.5 million if all options are exercised through 2032. The contract is entirely civilian, with no defense exposure, and carries a neutral signal (strength 6/10) due to the long-term revenue visibility offset by execution risk inherent in the fixed-price structure. The highest-conviction signal is the moderate revenue visibility for EPSILON INC, but the key risk is federal budget uncertainty and the potential for option non-exercise, which could materially reduce the $34.6 million annual run-rate implied by the full contract ceiling. Investors should monitor USDA option exercise announcements and AMERICAN SYSTEMS CORPORATION's financial disclosures for contract contribution details.

1 total filings
· daily

General Federal Contracts — July 15, 2026

This digest covers a single $83.4 million civilian contract awarded to EPSILON INC, a subsidiary of AMERICAN SYSTEMS CORPORATION, by the Department of Agriculture for DISC IT support services. The contract is entirely civilian, with no defense-related awards in the period. The dominant theme is stable, long-term civilian IT services, with the contract running through 2032 and a total potential value of $346.5 million if all options are exercised. The highest-conviction signal is neutral, reflecting a long-term revenue stream offset by firm-fixed-price execution risk and federal budget uncertainty. Key risks include option exercise dependency and potential budget constraints from continuing resolutions.

1 total filings
· daily

S&P 500 Technology Sector SEC Filings — July 15, 2026

The four filings for July 15, 2026, reveal a clear and concerning pattern of insider selling across the S&P 500 Technology sector, particularly concentrated in the cybersecurity sub-sector. The most significant signal is the aggressive selling by CrowdStrike's CEO and a Director, totaling over $3.4 million, which, combined with Datadog's CEO selling $10.8 million under a 10b5-1 plan, creates a bearish sentiment for high-growth software names. In contrast, Microsoft's filing is a routine tax withholding event with no strategic signal, highlighting the divergence between a mature mega-cap and its growth peers. The lack of any positive period-over-period comparisons, forward guidance, or capital allocation activity (buybacks/dividends) in these filings amplifies the negative tone. The primary takeaway is a potential loss of management conviction in the cybersecurity and observability sub-sectors, which warrants a defensive posture for investors until upcoming earnings calls provide fundamental context.

3 high priority 1 medium 4 total filings
· daily

Nasdaq 100 Stocks SEC Filings — July 15, 2026

The six filings for the NASDAQ-100 stream reveal a stark divergence between a single, high-quality growth story (ASML) and a cluster of insider selling activity at CoreWeave and Meta. ASML's Q2 2026 results are a standout, with strong revenue and net income, and a raised full-year outlook that signals robust demand for its semiconductor equipment. This positive sentiment is a powerful counterweight to the bearish signals from insider transactions. The most critical development is the concentrated insider selling at CoreWeave, where the Chief Development Officer has sold nearly all of his stake, and the CFO has also liquidated a significant position. This pattern, combined with Meta's COO selling over $1M in stock, creates a portfolio-level theme of management cashing out. The lack of period-over-period data for the insider filings limits trend analysis, but the sheer volume and nature of the sales are actionable red flags. The overall portfolio picture is one of a high-conviction long opportunity in ASML, offset by significant risk signals from insider behavior at other key holdings.

4 high priority 2 medium 6 total filings
· daily

US Activist Hedge Fund Institutional SEC 13D 13G — July 15, 2026

The July 15, 2026 batch of 50 filings reveals a dominant theme of passive institutional accumulation, particularly by Bank of Nova Scotia (BNS) and Pzena Investment Management, across diverse sectors including crypto-mining (CleanSpark, TeraWulf), defense tech (Voyager Technologies), and legacy manufacturing (Magna, Hooker Furnishings). Pzena has emerged as a significant, high-conviction holder, establishing or increasing stakes above 8% in six companies (Magna, Globant, Hooker, Amdocs, Corebridge, ScanSource), signaling a value-oriented thesis on these names. The most critical development is Warren Buffett's massive charitable donation of 9 million Berkshire Hathaway B-shares, a planned transfer that reduces his economic stake but maintains voting control. A notable activist development is the cooperation agreement at Repay Holdings, where a 9.38% holder secured a board seat, while Rayonier Advanced Materials is in play with a formal strategic alternatives process drawing interest from AIP. Several micro-cap filings (Vivos, Newton Golf, Elong Power) feature complex capital structures with beneficial ownership blockers, indicating high-risk, structured investments. Overall, the digest points to a market where large passive managers are rotating capital into mid-cap value, while select special situations (M&A, board fights) offer event-driven opportunities.

7 high priority 43 medium 50 total filings